The full-year cost of care for U.S. patients with obesity two years after starting on Novo Nordisk’s Wegovy or similar GLP-1 ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral GLP-1R agonist, Rybelsus, ...

RANCHO CORDOVA, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- iMD Companies, Inc. (OTC: ICBU) subsidiary Riize, LLC (Riize Health ...

Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the ...

The SOUL cardiovascular outcomes trial was a double-blinded, randomised trial that compared oral semaglutide to placebo as an ...

An oral formulation of semaglutide, taken daily, is more effective at reducing the risk of major adverse cardiovascular ...

The prevalence of obesity continues to remain high in the US making the demand for effective treatments even more urgent.

For years, people looking for weight management support have turned to injectable medications like Ozempic, which contains ...

Bernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...

A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients ...

Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.